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Abstract 
Background: Previous reviews have investigated the effectiveness of telemedicine in the treatment 
of heart failure (HF). Dependent variables have included hospitalizations, mortality rates, disease 
knowledge and health costs. Few reviews, however, have examined the variable of health-related 
quality of life (QoL). 
Methods: Randomized controlled trials comparing the delivery methods of any form of telemedicine 
with usual care for the provision of HF disease-management were identified via searches of all 
relevant databases and reference lists. To be included studies had to report a quantitative measure 
for mental, physical or overall QoL.  
Results: 33 studies were identified. However, poor reporting of data resulted in the exclusion of 7, 
leaving 26 studies with 7,066 participants. 3 separate, random effects meta-analyses were 
conducted for mental, physical and overall QoL. Telemedicine was not significantly more effective 
than usual care on mental and physical QoL (SMD 0.03, (95% CI -0.05-0.12), P = 0.45 and SMD 0.24, 
(95% CI -0.08-0.56), P = 0.14, respectively). However, when compared to usual care, telemedicine 
was associated with a small significant increase in overall QoL (SMD 0.23, [95% CI 0.09-0.37], P = 
0.001). Moderator analyses indicated that telemedicine delivered  over a long-duration (≥52 weeks) 
and via telemonitoring was most beneficial. 
Conclusion: Compared to usual care, telemedicine significantly increases overall QoL in patients 
receiving HF disease management. Statistically non-significant but nonetheless positive trends were 
observed for physical QoL, also. This provides preliminary support for the use of telemedicine in the 
management of heart failure without jeopardising patient well-being.  
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Introduction 
It was recently estimated that over 23 million people worldwide were living with heart failure 
(HF)[1]. The chances of developing the condition are estimated one in five [1], there is a high 
prevalence of re-hospitalization [2], and a high five-year mortality rate [3, 4]. Disease management 
programs have therefore been designed to stem the ever-rising costs associated with HF. 
Whilst disease management programmes have been shown to decrease mortality and hospital 
readmissions associated with HF [5-7], uptake to these programmes is extremely low. In the UK, the 
National Audit of Cardiac Rehabilitation [8] reported that fewer than 4% of all patients presented 
with HF as a primary diagnosis, despite 88% of cardiac rehabilitation centres offering support for this 
disease. Studies investigating low uptake to treatment have identified patient-related factors such as 
a lack of time or transport as common barriers [9, 10]. 
Telemedicine has the potential to alleviate problems of access to treatment for HF, especially in rural 
communities. Telemedicine is defined by the World Health Organisation [11], as ‘The delivery of 
health care services, where distance is a critical factor, by all health care professionals using 
information and communication technologies for the exchange of valid information for diagnosis, 
treatment and prevention of disease and injuries...’(P9). By allowing a medical practitioner to 
communicate with a patient remotely, the problems of transport and time are largely overcome. 
Research has shown telemedicine can significantly reduce both mortality and re-hospitalization rates 
[12, 13]. Additionally, home-based telemedicine can not only support health behaviour change, but 
can enhance disease-specific education and increase patient’s self-care. All of these may 
substantially reduce the burden on practitioners [14], and potentially reduce healthcare costs [15, 
16]. 
Published reviews of telemedicine have investigated multiple health-related variables, such as, 
hospitalizations, mortality rates and disease knowledge. To our knowledge, no recent published 
meta-analytic review has synthesised research investigating the effectiveness of telemedicine versus 
usual care on health-related quality of life (QoL) in the treatment of HF. This is despite relationships 
between low QoL and poor HF outcomes [17, 18]. Although Inglis et al., [12] have published some 
exemplary reviews which they have continued to update, the authors only describe and tabulate 
QoL and so do not include the variable in their meta-analysis. The aim of this systematic review is to 
synthesise research reporting the effects of telemedicine on the self-reported QoL of patients with 
HF.  
Method 
Inclusion criteria 
Whilst the risk of publication bias is always an issue [19], we believe that the results from large 
multi-centred published studies using rigorous methods could be diminished by the inclusion of 
unpublished studies. Furthermore, inclusion of the latter might increase the heterogeneity of the 
findings, rendering the aggregation of these via meta-analytical methods less reliable. We therefore 
only included published data. In further efforts to maintain the reliability and rigor of our analysis, 
we only included studies reporting the findings of randomised controlled trials (RCTs). 
Search strategy 
Keywords were “telemedicine”, “telehealth”, “telemonitoring”, “cardiac”, “cardiovascular”, “heart”, 
“rehabilitation”, “disease-management”, “intervention” and “secondary prevention”. These were 
entered into databases using the Boolean operators “AND” and “OR” to retrieve studies most 
appropriate to providing an overview of telemedicine in HF. Studies were selected if the articles 
contained the keywords anywhere in the text. Databases searched were: PubMed, Web of Science, 
Medline, Cochrane Library, Excerpta Medica Database (EMBASE), National Institute for Health 
Research (NIHR), Centre for Reviews and Dissemination (CRD), Database of Abstracts of Reviews of 
Effects (DARE), Psych Articles, Primo, Scopus and Google Scholar. Relevant journals, such as the 
Journal of Telemedicine and Telecare, the Journal of Cardiac Failure, and the European Journal of 
Cardiovascular Nursing were searched for studies not identified by the above searches. Reference 
lists of relevant studies and critical reviews were hand-searched. All searches were up to and 
including May, 2016.  
Study selection 
It is not surprising, given the multiple methods of telemedicine available, that a cursory review of the 
relevant literature reveals substantial methodological heterogeneity. We therefore set the following 
inclusion criteria. Studies were included in the meta-analysis if they were RCTs comparing any form 
of telemedicine delivered directly to a HF population, with standard post-discharge usual care. 
Studies had to be published in a peer-reviewed journal and report a quantitative measure of QoL. 
Any questionnaire measuring QoL was acceptable. Studies had to be written in English. We excluded 
studies conducted on the caregiver as opposed to the patient, and those that used a primary-
prevention population. 
Data collection 
The first author checked the title and abstract of each study identified against the 
inclusion/exclusion criteria. Full-text articles were retrieved and assessed. For studies included in the 
analysis, all relevant information was extracted, and SPSS v21 was used to store and categorise 
variables. Two authors applied the guidelines presented in SIGN-50 [20] to gauge the quality of the 
study; where there was disagreement, the third author mediated discussion to gain consensus. 
Analyses 
The primary outcome variable was health related quality of life (QoL), which was expressed via three 
components; mental, physical, and overall. Although a lack of clarity over the exact definition for the 
concept of QoL is evident [21, 22], Mental QoL refers to a patient’s perceptions of social functioning, 
vitality and emotions, and Physical QoL refers to a patient’s perceptions of pain, physical functioning 
and general health. Overall QoL involves aspects from both the mental and physical components 
[23-25].  
If an individual study reports 2 different components of QoL, where appropriate the remaining 
component will be inferred.  
Meta-analyses were conducted on each component of QoL separately. We used a random effects 
model and the standardized mean difference (SMD), and assessed heterogeneity using the Q 
statistic [26]. To mitigate for the Q statistic’s lack of power with small samples and excessive power 
with large samples [27], the  index [28] was also used. On the basis of generally equivalent 
attrition rates observed between experimental and control conditions in all studies, and in the 
absence of evidence for the otherwise, in studies reporting attrition between baseline and end-
point, it was assumed that participants were missing completely at random (MCAR).  
Standardized mean difference effect sizes were calculated using Hedges g [29] to accommodate 
different sample sizes across conditions. We employed the correction factor for positive bias 
proposed by Morris (equation 10) [30]. 95% confidence intervals were then calculated for each 
effect size (ES). Given between-study heterogeneity in relation to the reporting of statistical results, 
we needed to adopt several methods to calculate ES. Descriptions of each method are presented in 
Table 1. Forest and funnel plots were prepared using Review Manager 5.3. 
Moderator analysis 
Moderator analyses were conducted to identify variables that significantly influenced overall ES. 
Two possible moderators were identified from previous research; firstly the method of delivery [13], 
and secondly the duration of the intervention [31]. For the former analysis, studies were grouped 
into telemonitoring (TM; the monitoring of vital signs from a distance using equipment such as 
digital scales or small PDAs), telephone (TP; regular scheduled phone calls to monitor or provide 
educational coaching to a patient) and miscellaneous (M; studies which do not solely fit into either 
of the 2 previous categories, such as regularly scheduled video-conferencing). For the latter, studies 
were grouped post-hoc into ‘≤ 13 weeks’, ’>13 to <52 weeks’ and ‘≥ 52 weeks’, in which analysis the 
groups are non-similar in duration to avoid underpowered analyses. A third moderator analysis that 
sought to investigate the effect of geographical location, specifically rural and urban groups, was 
planned to test the hypothesis that the effects of telemedicine might be more pronounced in a rural 
setting. However, in almost all of the articles, it was unclear how large the catchment area was for 
each study and thus none could be reliably classified geographically.  
Results 
Study selection 
1,580 citations were identified and examined for relevance. Following exclusions, 266 studies 
remained and full-text copies were accessed. Details of the study exclusion process are presented in 
Figure 1. 
A total of 33 studies met the inclusion criteria (Table 2). However, due to poor reporting of 
descriptive statistics required to calculate effect sizes, a further 7 studies were excluded [32-38]. This 
was despite attempts to contact the respective authors to secure missing data. A funnel plot is 
shown in figure 2 detailing the risk of bias in the meta-analyses, where a summary of this bias is 
included in table 2 using the SIGN-50 guidelines. 3 studies [57, 67, 71] compared two different forms 
of telemedicine to usual care and from this point forwards are thus referred to as two separate 
studies. The studies included 12 that reported overall QoL only, 5 that reported both mental and 
physical QoL, and 9 studies that reported all three components of QoL. Furthermore, 1 study 
reported overall and physical QoL and 1 study reported physical QoL only. 1 study that compared 2 
forms of telemedicine [67] reported mental and physical QoL for one form of telemedicine (included 
in the total above) and only mental QoL for the other. A total of 5 included studies reported mental 
and physical but not overall QoL [47, 49, 54, 67, 72]. 4 of these studies used the SF-12/36 and thus 
an overall QoL score was not calculated, as the short form explicitly states that this is inappropriate. 
The remaining study used the MLHF questionnaire and did not report enough data for an overall 
score to be inferred. A total of 7,066 participants, from 10 different countries were included in the 
analysis. 16 of 29 studies, representing 3,515 participants, were conducted in the USA 
A total of 10 different questionnaires were used to measure QoL in the included studies; the 
Minnesota Living with Heart Failure Questionnaire (MLHF) [39], both the 36 and 12 item Short Form 
(SF-36 and SF-12, respectively) [40], the 8-item Short Form Health Survey (SFHS-8) [41], the General 
Health Questionnaire (GHQ) [42], the Kansas City Cardiomyopathy Questionnaire (KCCQ) [43], the 
Hospital Anxiety and Depression Scale (HADS) [44], the EuroQol (EQ-5D) [45] and the Psychological 
General Well-Being Index (PGWBI) [46]. A Polish variant of the SF-36 was also used in 2 studies [60, 
61]. 
Table 2: Description of included studies 
Study Intervention Duration of 
follow-up 
(weeks) 
Number of 
patients 
Mean age 
(years) 
Male sex 
(%) 
Country Type of QoL 
(Questionnaire used) 
Sign-50 
Antonicelli, et al. (2008) 
[47] 
Telemonitoring 52 57 78 61.5 Italy Mental + Physical (SF-36) + 
Artinian, et al. (2003) [48] Telemonitoring 13 18 68 94.5 USA All (MLHF) + 
Barth, V. (2001) [49] Structured telephone support 13 34 75 47 USA All (MLHF) + 
Copeland, et al. (2010) [50] Structured telephone support 52 458 70 99 USA Mental + Physical (SFHS-
8) 
- 
Dar, et al. (2009) [51] Telemonitoring + telephone 
support 
26 182 71 66.5 UK Overall (MLHF) ++ 
De Lusignan, et al. (2001) 
[52] 
Telemonitoring + video 
conferencing 
52 20 75  UK Overall (GHQ) - 
DeWalt, et al. (2006) [53] Structured telephone support 52 123 63 49 USA Overall (MLHF) ++ 
Dunagan, et al. (2005) [54] Structured telephone support 52 151 70 43.5 USA Mental + Physical (MLHF) ++ 
GESICA Investigators 
(2005) [55] 
Structured telephone support 52 1518 65 71 Argentina All (MLHF) ++ 
Goldberg, et al. (2003) [56] Telemonitoring 26 280 59 67.5 USA All (MLHF & SF-12) + 
Jerant et al. (2003) [57] Structured video conferencing 
support 
9 
 
25 70 48 USA 
 
All (MLHF) 
 
++ 
Structured telephone support 24 72 46 ++ 
Koehler, et al. (2011) [58] Telemonitoring 104 710 67 81.5 Germany Physical (SF-36) ++ 
Madigan, et al. (2013) [59] Telemonitoring 10 95 75 33.5 USA Overall (KCCQ) ++ 
Piotrowicz et al. (2014) [60] Telemonitoring 8 131 58 89.5 Poland All (PSF-36) + 
Piotrowicz, et al. (2015) 
[61] 
Telemonitoring 8 107 58 89 Poland Overall (PSF-36) + 
Ramaekers, et al. (2009) 
[62] 
Telemonitoring 13 101 72 61.5 Netherlands Overall (HADS) - 
Riegel, et al. (2006) [63] Structured telephone support 26 134 72 46.5 USA All (MLHF) ++ 
Schwarz, et al. (2008) [64] Telemonitoring 13 102 78 48 USA Overall (MLHF) ++ 
Seto, et al. (2012) [65] Telemonitoring  52 82 54 96.5 Canada All (MLHF) ++ 
Sisk, et al. (2006) [66] Structured telephone support 52 406 60 48.5 USA Overall + Physical (MLHF 
& SF-12) 
++ 
Smith, et al. (2005) [67] 
 
Structured telephone support 78 
 
715 71 72 USA 
 
Mental (SF-36)  + 
Structured telephone support + 
telemonitoring 
713 71 71 Mental + Physical (SF-36) + 
Stromberg, et al. (2006) 
[68] 
CD-ROM based education 26 154 70 71 Sweden Overall (EQ-5D) + 
Tomita, et al. (2009) [69] Internet-based education 52 40 76 32.5 USA Overall (CHFQ) + 
Villani, et al. (2014) [70] Telemonitoring 52 80 72 74 Italy Overall (PGWBI) + 
Wakefield, et al. (2008) 
[71] 
 
Structured telephone support 26 
 
96 70 99 USA 
 
Overall (MLHF) 
 
++ 
Structured video conferencing 
support 
101 68 98 + 
Wootton, et al. (2009) [72] Structured telephone support 52 409 83 68.5 Australia Mental + Physical (SF-12) + 
SF-36: 36-Item Short Form; MLHF: Minnesota Living with Heart Failure Questionnaire; SFHS-8: 8-item Short Form Health Survey; GHQ: General Health Questionnaire; SF-12: 
12-item Short Form; KCCQ: Kansas City Cardiomyopathy Questionnaire; PSF-36: Polish Version of the SF-36; HADS: Hospital Anxiety and Depression Scale; EQ-5D: EuroQoL; 
CHFQ: Congestive Heart Failure Questionnaire; PGWBI: Psychological General Well-Being Index; ++: high quality; +: acceptable; -: low quality.
Overall QoL 
22 studies measured the effect of telemedicine on overall QoL (Figure 3). The MLHF was the most 
commonly used measure (N = 14). Telemedicine was found to be more effective than usual care in 
improving overall QoL in HF patients (SMD 0.23, [95% CI 0.09-0.37], P = 0.001,  = 34%). The Q 
statistic was non-significant at the P = 0.05 level; this is supported by the  index showing only a low 
level of heterogeneity in the results (33.8%). Using Cohen’s thresholds for interpreting effect sizes 
[73], 0.23 indicates a small positive effect for telemedicine when compared to usual care. 
Mental QoL 
15 studies examined the effect of telemedicine on mental QoL. The two main measures used were 
the MLHF (N = 8) and 2 different itemed Short Forms (12, 36; N = 6). Random-effects meta-analysis 
indicated that telemedicine was equally effective as usual care in improving mental QoL (SMD 0.03, 
(95% CI -0.05-0.12), P = 0.45,  = 0%). The Q statistic was again non-significant at the P = 0.05 level, 
with the  index showing no heterogeneity in the results also (0%). 
Physical QoL 
16 studies examined the effect of telemedicine for heart failure on physical QoL. Similar to mental 
QoL, the MLHF and the 12 and 36 item versions of the Short Form, were the most common 
questionnaires used to measure physical QoL; with 8 and 7 studies using each questionnaire 
respectively. The aggregation of the effect sizes using a random-effects model indicated that 
telemedicine had a slightly larger effect than a usual care control condition, although this effect was 
not statistically significant (SMD 0.24, (95% CI -0.08-0.56), P = 0.14,  = 2%). The Q statistic was not 
significant at the P = 0.05 level, which was supported by the  index being classified as low (2.1%).  
 
 
Figure 3: Forest plot showing effect sizes for telemedicine vs. usual care 
 
Moderator analyses 
In evaluating the moderating effects of the mode of telemedicine delivery, 11, 11 and 7 studies fell 
into TM, TP and M categories respectively. Studies in the M category were characterised by 
heterogeneous delivery methods. This category included studies which either used delivery methods 
that did not fit into the 2 previously mentioned categories (for example, video-conferencing or 
internet-based interventions) or methods that employed elements from both the TM and TP 
categories. 
In TM a positive and significant effect on overall QoL was observed when compared to usual care 
(SMD 0.34, df = 8, P = 0.02). Contrastingly, no statistically significant effects were observed for TP 
(SMD 0.22, df = 6, P = 0.06) or M (SMD 0.04, df = 5, P = 0.62). 
Effects on mental QoL were non-significant for TM (SMD 0.13, df = 4, P = 0.18), TP (SMD 0.00, df = 7, 
P = 1.00) and M (SMD 0.06, df = 1, P = 0.44). The M group however, incorporated only 2 studies and 
thus may be considered underpowered. Likewise effects on physical QoL, were non-significant for TP 
(SMD 0.07, df = 7, P = 0.68), and M (SMD 0.00, df = 1, P = 0.95), whilst a large effect size approaching 
statistical significance was observed for TM (SMD = 0.59, df = 5, P = 0.08). The M analysis was again 
conducted with only 2 studies. 
A second moderator analysis evaluated the effect of intervention duration. For ease, the groups, 
≤13, >13 to <52 and ≥52 weeks will henceforth be referred to as short, medium and long, 
respectively. Groups contained 9, 6 and 14 studies, respectively. 
For overall QoL no significant effect of the short (SMD 0.23, df = 8, P = 0.09) or medium (SMD 0.10, 
df = 5, P = 0.25) durations was evident when compared to usual care. In long, a significant effect 
(SMD 0.37, df = 6, P = 0.02) indicated that over longer periods, telemedicine was more effective than 
usual care. Care must be taken in interpreting this result; however, as the  index showed that the 
long intervention length had substantial heterogeneity (61.5%). No significant effects for duration 
were observed when comparing telemedicine to usual care in mental QoL (Short: SMD 0.02, df = 4, P 
= 0.88; Medium: SMD -0.02, df = 1, P = 0.84; Long: SMD 0.05, df = 7, P = 0.39) or physical QoL (Short: 
SMD 0.51, df = 4, P = 0.23; Medium: SMD 0.07, df = 1, P = 0.67; Long: SMD 0.15, df = 8, P = 0.48). 
Discussion 
Findings indicate that telemedicine is not inferior to usual care in the maintenance of mental and 
physical QoL in patients with HF and is significantly more effective than usual care in maintaining 
overall QoL. Moderator analyses indicate that whilst TP and M are as effective as usual care, TM is 
more effective in the maintenance of QoL. 
Although it is not clear why TM should be associated with a larger positive effect than TP and M, it 
could be due to the continuous support that TM is able to provide. This allows for early identification 
of complications or disease progression, and supports adherence to disease management 
programmes [74]. Within physical QoL, TM was also associated with a moderate SMD (0.59), 
suggesting that this delivery method is substantially more effective than usual care. This effect, 
although approaching significance (P = 0.08), was not statistically significant at the 0.05 level. Whilst 
this result became significant with a much larger effect when utilizing a fixed effects model, this 
approach does not facilitate generalizability and also works on the assumption that there is one 
single true effect [75]. Given the possible differential effect of study-level moderators (age of the 
patient, acceptance to technology, etc.), and the substantial heterogeneity between studies 
( =96%), the use of random effects is warranted.   
Previous studies have reported that although telemedicine requires initial financial investment, over 
a long period such interventions prove to substantially reduce medical costs [75]. Our moderator 
analysis for intervention duration indicated that although shorter duration interventions were not 
inferior when compared to usual care and thus there are clear reasons that such interventions may 
be adopted; telemedicine delivered over a long period (≥52 weeks) was associated with a larger 
effect than usual care, perhaps supporting both financial and ethical arguments for the broader 
adoption of telemedicine in this context.   
The calculation of ES is straight forward, requiring as few as 2 means and standard deviations. The 
latest edition of the American Psychological Association publication manual describes the inclusion 
of these descriptive data-points as “essential” [77]. However, over and above the majority of studies 
failing to report the ES, almost 20% of studies meeting the inclusion criteria failed even to report 
data allowing ES to be calculated. Furthermore, of those that did, a wide variety of descriptive 
methods were reported requiring the use of multiple equations to calculate the statistic in question. 
This poor reporting of even the most basic descriptive data suggests that strict guidelines need to be 
implemented and enforced by journals to facilitate the systematic synthesis of findings, something 
that should be a core objective of all involved in research.  
The methodological shortcomings of some of the included articles in this meta-analysis are not 
restricted to the under reporting of descriptive statistics. One advantage of the implementation of 
telemedicine direct to the home, is that patients do not need to travel for extended periods of time 
to attend disease management programmes; with the increased time it takes patients who live in 
rural areas to travel, or who face restrictions on movement due to disability, age, demographic or 
time constraints, this advantage is arguably multiplied. On the basis that most studies failed to 
report location, specifically patient location and/or hospital catchment areas, it is impossible to 
measure the efficacy of disease management delivered via telemedicine to rural patients. Future 
research should aim to rectify this situation so that possible geographical effects can be identified 
and researched further. 
TM and TP delivery methods were used in over 75% of the included studies, and it is therefore hard 
to disagree with Kotb, et al.’s conclusions that the lack of data pertaining to less common delivery 
methods (for example, video-conferencing or internet-based interventions) is limiting our current 
understanding of their potential efficacy [13]. Future research should strive to increase the literature 
on less common delivery methods, so that medical practitioners have available data on the positives 
and negatives associated with each mode of delivery. 
In summary, data suggest that when compared with usual care, telemedicine is equally effective in 
the maintenance of physical and mental QoL but is more effective in relation to overall QoL. Our 
moderator analysis suggests that disease management received over a long duration via TM is most 
beneficial for overall QoL. This could be due to the continuous nature of TM facilitating early 
awareness of disease progression, and the longitudinal nature of TM promoting adherence to 
disease management programmes. This benefit is magnified by the increasingly low costs of TM 
compared to usual care over time [75]. These data provides preliminary support for the use of 
telemedicine in the management of heart failure without jeopardising patient well-being.  
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Appendices  
Table 1: Effect size equations 
Study reports How effect size was calculated 
1. Pre/post means and 
SDs 
Used 
 
 
 
Where M = mean, T = the treatment condition, C = the 
control condition and  is given by 
 
. 
 
As described by Carlson and Schmidt (equation 1) [78].  
2. Mean change (delta 
scores) and SD of the 
change 
Used between groups, single test, Hedges g, given by 
 
, 
 
where  is calculated as above accept using the 
SD of the mean change. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. End-point p-values 
with no baseline 
differences 
p-values were transformed into z-scores and then g 
was calculated by  
 
. 
 
As described by DeCoster (equation 5.11) [79]. 
4. Paired sample t-
statistic for each 
condition 
Decoster [79] gives g from a t-statistic as 
 
. 
 
Because the t-statistic here represents a paired 
sample, g is calculated separately for each condition 
and then combined using Becker’s method [76], shown 
by: 
 
 where  and  = Hedges g for 
the treatment and control conditions, respectively and 
 and  are correction factors approximated by 
 
 
 
As detailed by Morris [27]. 
Figure 2: Funnel plot assessing risk of bias 
 
 
